<DOC>
	<DOCNO>NCT00691210</DOCNO>
	<brief_summary>The purpose study test safety combination two anticancer medicine , call vorinostat etoposide , high dose vitamin call niacinamide . These medication test different dose level . The investigator want find effect , good and/or bad , patient recurrent lymphoma . The first two drug , vorinostat niacinamide , suppress survival signal lymphoma cell depend . The third drug , etoposide kill sensitive lymphoma cell alone combination chemotherapy drug . Vorinostat anticancer agent approve Food Drug Administration use cutaneous T-cell lymphoma . It evaluate study combination anticancer medicine use type lymphoma . Vorinostat 's use combination anticancer regimens experimental . Niacinamide vitamin investigational experimental give high dos anticancer agent . Niacinamide yet approve Food Drug Administration use lymphoma . Etoposide approve Food Drug Administration use aggressive non-Hodgkin 's lymphoma . However , way give clinical study experimental .</brief_summary>
	<brief_title>Phase I Vorinostat Combination With Niacinamide Etoposide Lymphoid Malignancies</brief_title>
	<detailed_description>Subjects treat vorinostat administer orally daily dose 14 day 21-day treatment cycle combination niacinamide administer orally 14 day 21-day treatment cycle etoposide administer intravenously day 8,9 10 21-day treatment cycle . Etoposide dose escalate MTD determine .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Histologically confirm relapsed refractory nonHodgkin 's lymphoma Hodgkin 's Disease ( WHO criteria ) , unwilling unable undergo autologous stem cell transplant 2 . Must receive first line chemotherapy . No upper limit number prior therapy 3 . Evaluable Disease 4 . Age &gt; 18 year 5 . ECOG performance status &lt; 2 6 . Life expectancy great 3 month 7 . Patients must adequate organ marrow function 8 . Adequate Contraception 9 . Ability understand willingness sign write informed consent document 1 . Prior Therapy Patients chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 4 week earlier Patient systemic steroid stabilize equivalent ≤10 mg/day prednisone 7 day prior start study drug No monoclonal antibody within 3 month unless evidence progression 2 . Patients may receive investigational agent 3 . Patients known central nervous system metastasis , include lymphomatous meningitis 4 . History allergic reaction attribute compound similar chemical biologic composition vorinostat , niacinamide etoposide 5 . Uncontrolled intercurrent illness 6 . Pregnant woman 7 . Nursing woman 8 . Active concurrent malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) . If history prior malignancy , patient must diseasefree ≥ 3 year 9 . Patient known Human Immunodeficiency Virus ( HIV ) positive 10 . Active Hepatitis A , Hepatitis B , Hepatitis C infection 11 . Patient history surgery would interfere administration absorption oral study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>